跳至主要内容

Medicilon Assists Hebei Changshan Biochemical Pharmaceutical Co obtain approval for clinical research on Class 1 new drug CSCJC3456 tablets

On January 8, 2024, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan Pharmaceutical) issued an announcement, saying that its holding subsidiary Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. has recently received the approval of the National Medical Products Administration (NMPA) to issue a "Drug Clinical Trial Approval Notice" for the new Class 1 chemical drug CSCJC3456 tablets.



Shanghai Medicilon Inc. (Medicilon), as a partner of Changshan Pharmaceutical, has efficiently completed most of the preclinical research work of CSCJC3456, including drug efficacy, pharmacokinetics and safety evaluation promoting the project to quickly complete the preclinical research and development process.

Accelerate Drug Innovation and Development 
   Medicilon’s One-Stop Shop to Assist Drug Preclinical Research and Development

As a one-stop preclinical R&D service platform, Medicilon actively expands its development layout in popular areas of innovative drugs and continues to pay close attention to the trend of oncology drug R&D.  Medicilon has established more than 370 tumor drug efficacy evaluation models, including humanized tumor transplant models, xenograft tumor transplant models, transgenic mouse tumor models, etc.  In addition, Medicilon has comprehensive preclinical research service capabilities and can provide systematic in vivo pharmacodynamics, pharmacokinetics, and safety evaluation research services that comply with both Chinese GLP and U.S. GLP standards.  Medicilon has also obtained AAALAC certification and complies with NMPA, FDA GLP standards.  Medicilon has participated in the research and development of new drugs and generic drug projects, and 420 of them have passed the approval of NMPA, FDA, and TGA and entered clinical trials.

About Changshan Pharmaceutical

Changshan Pharmaceutical was established in 2000. It is one of the few leading companies in China that has a complete industrial chain of heparin products and is able to engage in the research, development, production and sales of crude heparin, heparin raw materials and heparin preparations.  In 2011, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was listed on the ChiNext of Shenzhen Stock Exchange (stock code: 300255).

Changshan Pharmaceutical is committed to the research, development, production and sales of innovative drugs in the fields of cardiovascular and cerebrovascular diseases, diabetes, tumors and other major diseases.  It has 2 national-level R&D platforms, 3 provincial-level R&D platforms, and 2 projects have been selected as major national science and technology projects for “Major New Drug Creation”.  At present, the Phase III clinical study of the Class 1 new drug ebenatide developed by the holding subsidiary has been successfully completed, and a new drug marketing application will be submitted soon.  The new drug clinical trial application (IND) in China for the Class 1 new drug CSCJC3456 tablets has been approved by the National Medical Products Administration (NMPA).

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文